 This study used claims data from the U.S. to evaluate the comorbidity burden among patients with vitiligo, finding that they were more likely to be diagnosed with autoimmune or psychiatric comorbidities, which contributed to increased economic burden and lower quality of life. This article was authored by Khaled Ezzedine, Ahmed M. Solomon, Chowli, and others.